Dublin, March 12, 2026 (GLOBE NEWSWIRE) — The “Connected Drug Delivery Devices Market (3rd Edition): Distribution by Type of Device, Mode of Connectivity, Route of Administration, Therapeutic Area & Geographical Regions – Trends and Forecast Till 2035” report has been added to ResearchAndMarkets.com’s offering.
The global connected drug delivery market is estimated to grow from USD 5.3 billion in the current year to USD 12.7 billion by 2035, at a CAGR of 10.2% during the forecast period, till 2035.
Over the years, poor compliance to prescribed medications continues to be a significant issue in the healthcare field, leading to disease progression, increased hospitalization rates, mortality, and rising healthcare expenses. Studies indicate that approximately 66% of individuals in the United States receive at least one prescription, yet nearly 50% fail to adhere to their physicians’ instructions for medication use. This challenge of non-adherence arises from multiple factors, such as complicated dosing regimens, restricted access to medications, and inadequate patient assistance. To address this, healthcare professionals and technology providers are using various strategies to streamline dosage plans, provide individualized medication schedules, and improve patient education.
Connected drug delivery devices represent a viable solution as these devices integrate traditional delivery methods with digital health technologies to improve adherence. These devices come with advanced features, sensors, and wireless connectivity that allow for smooth integration with mobile apps, digital health platforms, and electronic health records. Additionally, the linked drug delivery system allows for real-time tracking of medication consumption and patient health conditions, thus facilitating prompt clinical interventions and customized therapy modifications. By enhancing patient involvement and adherence, these devices not only bolster patient results but also help in reducing total healthcare costs.
Further, the integration of sensor technologies has transformed the capabilities of conventional drug delivery systems, allowing them to evolve into intelligent, interconnected solutions. Ongoing advancements in telehealth integration and broader acceptance of digital health tools are anticipated to fuel consistent growth in the connected drug delivery device market in the upcoming years.
Growth Drivers: Strategic Enablers of Market Expansion
Rising chronic disease prevalence, including diabetes, asthma, chronic obstructive pulmonary disease (COPD), and autoimmune disorders, fuels demand. This is due to the fact that connected drug delivery devices enable precise dosing and long-term therapy management. Technological advances in sensors, Bluetooth Low Energy, AI analytics, and IoT integration allow remote monitoring, data sharing with providers, and personalized interventions, boosting adherence and outcomes. Patient engagement and aging populations further accelerate growth, with market projections showing a higher CAGR driven by telehealth synergies and precision medicine shifts.
Market Challenges: Critical Barriers Impeding Progress
Connected drug delivery devices, which integrate sensors and apps for real-time adherence tracking and remote monitoring in chronic conditions like diabetes and asthma, face multifaceted market challenges that hinder their widespread adoption. High development and manufacturing costs driven by advanced sensors, R&D, precision assembly, and supply chain issues elevate prices above traditional devices, compounded by ongoing cloud fees, tariffs, and payer reimbursement gaps. Further, stringent regulatory hurdles for drug-device combinations and global compliance delays, clash with rapid tech evolution and limit AI innovations. In addition, cybersecurity and data privacy risks hamper user trust and restrict data sharing, while usage barriers like usability issues persist.
Connected Drug Delivery Devices Market: Key Segments
Connected / Smart Wearable Injectors Account for the Largest Market Share
In the current year, the connected / smart wearable injectors holds the largest market share, and this trend is expected to persist in the coming years. This is due to the increasing prevalence of chronic diseases and the ongoing initiatives of stakeholders to incorporate enhanced features into their connected drug delivery devices. These improvements enhance monitoring, strengthen patient compliance, and allow data exchange with healthcare professionals.
Bluetooth-Enabled Connected / Smart Devices Hold the Highest Share in the Future
At present, Bluetooth-enabled connected / smart devices are expected to capture a larger share of the connected drug delivery devices market. Moreover, this segment is expected to experience substantial growth during the forecasted period. This is because Bluetooth connectivity is simple to set up, widely accessible on all smartphones, and operates without requiring any additional devices.
Parenteral Segment Holds the Highest Connected Drug Delivery Devices Market Share in the Current Year
According to our estimates, in the current year, the parenteral segment is likely to hold a larger market share. This is because it is the favored route for administering biologics and high-value treatments for chronic conditions. Further, the inhalation segment is expected to experience a higher CAGR over the forecast period, owing to the ease, versatility, and painless nature of drug delivery through this method, along with its ability for prolonged localized therapeutic effect.
North America Dominates the Market by Securing Highest Share
According to our estimates, North America is expected to dominate the connected drug delivery devices market share this year. Further, the Asia-Pacific market is expected to expand at a comparatively higher rate till 2035. The growth is driven by a rising number of biopharmaceutical start-ups, significant research and development efforts for innovative drug delivery systems, and an increase in device approvals for various disease therapies in this area.
Connected Drug Delivery Devices Market: Key Insights
- The current market landscape features the presence of more than 80 manufacturers that offer various connected drug delivery devices; of these, majority are headquartered in North America.
- Nearly 75% of the connected / smart drug delivery devices are currently commercially available; notably, most of these devices are intended for the administration of medications via subcutaneous route.
- At present, over 30 innovative add-on sensors are available / under development for integration with conventional drug delivery devices; numerous add-on sensor manufacturers are start-ups based in Europe.
- More than 55% of the add-on sensors are designed for drug delivery via inhalation; of these, over 85% of the sensors can support Bluetooth connectivity.
- The majority of clinical trials registered in this domain till date have evaluated the safety and efficacy of various connected drug delivery devices; most of these studies have been conducted across multiple sites in the US.
- The growing interest of stakeholders in this market is reflected from the rising partnerships established among various stakeholders in the recent past; in fact, close to 70% of the deals were inked in the last three years.
- Investors are increasingly channelizing capital into connected drug delivery devices market for the development of advanced devices which are accelerating industry advancements.
- The development process of a connected / smart drug delivery device involves various steps, ranging from planning, designing, engineering, process validation, manufacturing and assembly to commercialization.
- The pioneer-migrator-settler map in blue ocean strategy analysis suggests that several connected drug delivery devices manufacturers focused on enhancing their products are likely to emerge as pioneers in the coming years.
- Owing to the ability of connected drug delivery devices to provide precise dosing and remote patient monitoring, the market is anticipated to witness a notable growth (CAGR of 10.2%) over the next decade.
- The connected drug delivery devices market in North America is expected to capture maximum share by 2035; further, majority of the devices manufactured for drug delivery are intended for metabolic disorders.
- Driven by the growing adoption of smart and connected drug delivery solutions in the US, the connected drug delivery devices market is poised to grow at a higher CAGR over the forecast period.
- Given the surge in demand for advanced drug delivery devices and the rising prevalence of chronic diseases, the connected drug delivery devices market is anticipated to rise steadily.
Primary Research Overview
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:
- Senior Director, Global Strategic Marketing, Medical, Large Company, US
- Co-Founder and Chief Executive Officer, Small Company, US
- Chief Executive Officer, Small Company, US
- Chief Executive Officer and President, Mid-sized Company, US
- Chief Executive Officer, Small Company, Italy
- Vice President and Chief Scientist, Large Company, Israel
- Director of Global Communications, and Former Vice President of Strategic Partnerships and Business Development, Mid-sized Company, US
- Former Chief Executive Officer, Small Company, US
- Former Director of Front-end Innovation and Head of Connected Health, Large Company, US
- Former Vice President, Marketing and Alliance Management, Mid-sized Company, US
- Advisor of Strategy and Business Development, Small Company, US
Companies Featured
- Bigfoot Biomedical
- BIOCORP
- Eitan Medical
- E3D Elcam Drug Delivery Device
- EoFlow
- Gerresheimer
- Insulet
- Medtronic
- Medtrum
- Nemera
- Phillips-Medisize
- Roche
- Sonceboz
- SOOIL Development
- Tandem Diabetes Care
- West Pharmaceutical Services
- Ypsomed
Additional Benefits
- Complementary PPT Insights Pack
- Complimentary Excel Data Packs Covering All Analytical Modules
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 500 |
| Forecast Period | 2026 – 2035 |
| Estimated Market Value (USD) in 2026 | $5.3 Billion |
| Forecasted Market Value (USD) by 2035 | $12.7 Billion |
| Compound Annual Growth Rate | 10.2% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/pi6sgq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Connected Drug Delivery Devices Market
